EPHA2 blockade overcomes acquired resistance to EGFR kinase inhibitors in lung cancer

Despite the success of treating EGFR mutant lung cancer patients with EGFR tyrosine kinase inhibitors (TKIs), all patients eventually acquire resistance to these therapies. Although various resistance mechanisms have been described, there are currently no FDA-approved therapies that target alternati...

Full description

Saved in:
Bibliographic Details
Published in:Cancer Res
Main Authors: Amato, Katherine R., Wang, Shan, Tan, Li, Hastings, Andrew K., Song, Wenqiang, Lovly, Christine M., Meador, Catherine B., Ye, Fei, Lu, Pengcheng, Balko, Justin M., Colvin, Daniel C., Cates, Justin M., Pao, William, Gray, Nathanael S., Chen, Jin
Format: Artigo
Language:Inglês
Published: 2016
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4715957/
https://ncbi.nlm.nih.gov/pubmed/26744526
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-15-0717
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items